Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 21,004 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ONE Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

NCT02980042
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Rituximab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 30, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency

NCT01379469
View directory record Official record
Conditions
Alpha-1-antitrypsin Deficiency, Liver Cirrhosis
Interventions
Drug-Carbamazepine (Tegretol XR), Carbamazepine (Tegretol XR) Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Combining Attention and Metacognitive Training to Improve Goal Directed Behavior in Veterans With TBI

NCT04044456
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Goal Management Training, Attention Training, Brain Health Workshop, National geographic movies
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 30, 2026, 5:46 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Scalable Digital Delivery of Evidence-based Training for Family to Maximize Treatment Admission Rates of Opioid Use Disorder in Loved Ones

NCT05666856
View directory record Official record
Conditions
Community Reinforcement And Family Training, Family Health, Substance-Related Disorders
Interventions
Community Reinforcement And Family Training, We The Village Peer Community Forum
Behavioral
Lead sponsor
We The Village, Inc.
Other
Eligibility
19 Years and older
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects

NCT00918229
View directory record Official record
Conditions
Prostate Cancer
Interventions
balloon implant, Balloon implantation
Device · Procedure
Lead sponsor
BioProtect
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Oct 30, 2026, 5:46 PM EDT
Completed No phase listed Observational

Clinical Outcomes of Patients with a Light Adjustable Lens (LAL) in At Least One Eye

NCT06016231
View directory record Official record
Conditions
IOL
Interventions
Light Adjustable Lens
Device
Lead sponsor
Bucci Laser Vision Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 30, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

NCT03266653
View directory record Official record
Conditions
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
Interventions
cytotoxic t-lymphocytes
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Month to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 5:46 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

NCT04868253
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
EMB-01
Drug
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 30, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Linking Somatic Mutation Rate With Baseline Exposure in East Palestine

NCT06357845
View directory record Official record
Conditions
Somatic Mutation
Interventions
Survey, Biological specimen collection, Communications about study updates and future research opportunities, Qualitative interview
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01345045
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-639, pregabalin, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)

NCT04599972
View directory record Official record
Conditions
Presbyopia
Interventions
CSF-1, Vehicle
Drug
Lead sponsor
Orasis Pharmaceuticals Ltd.
Industry
Eligibility
45 Years to 64 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 30, 2026, 5:46 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

NCT04644770
View directory record Official record
Conditions
Prostatic Neoplasms, Adenocarcinoma
Interventions
JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00121173
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 30, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Comparison of Latanoprost Vs. Timolol

NCT00579969
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Timolol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

NCT05142722
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions
Placebo, Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
2,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 30, 2026, 5:46 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Methods to Treat Multiple Gingival Recession Defects

NCT03124329
View directory record Official record
Conditions
Gingival Recession
Interventions
Coronally Advanced Flap, Intrasulcular Tunneling, Vestibular Incision Subperiosteal Tunnel Access (VISTA), Leukocyte-Platelet Rich Fibrin (L-PRF)
Procedure · Biological · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

NCT01102972
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 30, 2026, 5:46 PM EDT
Recruiting Phase 1 Interventional

177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

NCT07145177
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Cancer
Interventions
177Lu-PSMA-617, Ablation, Trans-arterial chemoembolization (TACE), Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Questionnaire
Drug · Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 5:46 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of BLKR201 in Healthy Adult Participants

NCT07501039
View directory record Official record
Conditions
Healthy
Interventions
BLKR201, Placebo
Drug
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

FMT In High-Risk Acute GVHD After ALLO HCT

NCT04139577
View directory record Official record
Conditions
Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 30, 2026, 5:46 PM EDT
Not listed Not applicable Interventional

TReatment Of Pulmonary HYpertension 1-US Study

NCT02835950
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Therapeutic Intra-Vascular UltraSound (TIVUS™) System
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Diego, California • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)

NCT00993291
View directory record Official record
Conditions
Parkinson Disease
Interventions
Frequency change to 60 Hz, Frequency change to 130 Hz
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

NCT03242018
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Guntersville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 30, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Renal Function
Interventions
Dapagliflozin 10 MG [Farxiga]
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 30, 2026, 5:46 PM EDT